Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $17

Benzinga Newsdesk www.benzinga.com Negative 93.1%

Neg 93.1% Neu 0% Pos 0%

Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $20 to $17.